Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 10/20 | 0.76 |
| ▸ | PNP | P00491 | 7/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | POLA1 | P09884 | 1/20 | 0.51 |
| ▸ | POLG | P54098 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | EDNRA | P25101 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | HBB | P68871 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6903598 | 0.86 | HPRT1 (0.86) | HPRT1PNPUSP2TSHREDNRA | |
| SCHEMBL9858327 | 0.82 | HPRT1 (0.58) | HPRT1PNPPOLBPOLA1POLG | |
| SCHEMBL9054025 | 0.80 | HPRT1 (0.80) | HPRT1PNP | |
| SCHEMBL6004502 | 0.80 | HPRT1 (0.67) | HPRT1PNPBLM | |
| SCHEMBL9858115 | 0.80 | HPRT1 (0.63) | HPRT1PNPPOLBPOLA1POLG | |
| SCHEMBL5557417 | 0.79 | HPRT1 (0.62) | HPRT1PNPUSP2TSHREDNRA | |
| SCHEMBL6316076 | 0.79 | FGFR1 (0.61) | HPRT1 | |
| Gs-438 SCHEMBL64567 | 0.78 | POLB (0.80) | HPRT1PNPPOLBPOLA1POLG | |
| SCHEMBL8896276 | 0.78 | HPRT1 (0.81) | HPRT1PNPPOLBPOLA1POLG | |
| SCHEMBL9417159 | 0.78 | HPRT1 (0.63) | HPRT1PNPPOLBPOLA1POLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040014722-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014722-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | NSUN2, POLR2H, NSUN3 | HPRT1 871/4885PNP 71/4885POLB 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.